Canadian liver journal · 2021
HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Julie H, Peltekian Kevork M
Аннотация
BACKGROUND: Since December 2019, there are 30 million confirmed cases of a novel coronavirus disease (COVID-19) secondary to severe acute respiratory syndrome coronavirus 2. As of 2020, hepatitis B virus (HBV) affects more than 200 million people worldwide. Both are caused by viral agents. The short-term mortality rate from COVID-19 is much higher than that of HBV.
OBJECTIVE: We sought to understand the impact of HBV coinfection on hospitalized patients with COVID-19.
SEARCH METHODS: Searches of the literature were conducted in the PubMed, Cochrane Library, and Embase electronic databases.
SELECTION CRITERIA: We included cohort studies and randomized studies with information on rates of mortality and intensive care unit (ICU) admission from individuals coinfected by HBV and COVID-19.
DATA COLLECTION AND ANALYSIS: Data from six cohort studies with 2,015 patients were collected between January and April 2020, and the results were analyzed by meta-analysis.
MAIN RESULTS: HBV coinfection did not lead to increased mortality or ICU admission rates among individuals hospitalized for COVID-19 (risk ratio 0.79, 95% CI 0.333-1.83, N = 2,015; adjusted OR = 0.79, 95% CI 0.31-1.98). During their hospital stay, coinfected patients did not appear to have an increased hospital length of stay or risk of hepatitis B reactivation.
CONCLUSIONS: This systematic review and meta-analysis provides support that HBV is not a significant risk factor for serious adverse outcomes among patients hospitalized for COVID-19 infection.
OBJECTIVE: We sought to understand the impact of HBV coinfection on hospitalized patients with COVID-19.
SEARCH METHODS: Searches of the literature were conducted in the PubMed, Cochrane Library, and Embase electronic databases.
SELECTION CRITERIA: We included cohort studies and randomized studies with information on rates of mortality and intensive care unit (ICU) admission from individuals coinfected by HBV and COVID-19.
DATA COLLECTION AND ANALYSIS: Data from six cohort studies with 2,015 patients were collected between January and April 2020, and the results were analyzed by meta-analysis.
MAIN RESULTS: HBV coinfection did not lead to increased mortality or ICU admission rates among individuals hospitalized for COVID-19 (risk ratio 0.79, 95% CI 0.333-1.83, N = 2,015; adjusted OR = 0.79, 95% CI 0.31-1.98). During their hospital stay, coinfected patients did not appear to have an increased hospital length of stay or risk of hepatitis B reactivation.
CONCLUSIONS: This systematic review and meta-analysis provides support that HBV is not a significant risk factor for serious adverse outcomes among patients hospitalized for COVID-19 infection.